Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Division of Molecular Genetics

Prof. Dr. Peter Lichter


We are interested in pathomechanisms of tumorigenesis and their relevance for the development of new strategies of tumor diagnosis and therapy.

One focus is the elucidation of genetic heterogeneity within tumor cell populations. The genetic pattern represents a "snapshot" of the clonal or subclonal composition of a tumor, and through appropriate longitudinal analyses we use this to track and model tumor evolution. Since this often leads to the outgrowth of individual tumor cell clones in dependence on therapeutic measures, we use this to develop hypotheses on mechanisms that can lead to therapy resistance. We are testing these in preclinical models in vitro and in vivo, including the use of patient-derived cell systems. Ultimately, these approaches serve to successfully counter therapy resistance.

Tumor heterogeneity interests us on the one hand at the level of neoplastic cells. Besides mechanisms to maintain genome stability, our particular research focuses on factors that regulate metabolic processes in the cell. On the other hand, we are interested in non-malignant cells in the tumor microenvironment, i.e. cells of the stroma and immune system. In addition, we investigate the potential pathogenic role of micro-organisms via extensive microbiome analyses in tumor or tumor-near tissue.

For potential clinical applications, we develop and validate predictive markers and gene signatures based on extensive molecular profiling of tumor cells at the level of genome, methylome, transcriptome, and other classes of molecular and cellular structures. This led to the implementation of an active workflow for Personalized Oncology based on genomic and transcriptomic data contributing to alternative or new therapy suggestions within regular Molecular Tumor Boards. Within the NCT Molecular Precision Oncology program (


Prof. Dr. Peter Lichter
Molecular Genetics (B060)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 6221 42 4619
Fax: +49 6221 42 4639

how to find us:

Selected Publications

  • Zapatka, M. et al. The landscape of viral associations in human cancers. Nature Genetics 52, 320-330 (2020)
  • Körber, V. et al. Evolutionary trajectories of IDH-wildtype glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell 35, 692-704 (2019)
  • Northcott P.A., et al. The whole genome landscape of medulloblastoma subtypes. Nature 547, 311-317 (2017)
  • Hanna BS, Llaó Cid L, Iskar M, Roessner PM, … Lichter P, Zapatka M, SeiffertM. Interleukin10-receptor signaling promotes the maintenance of a PD-1 int, TCF-1 +, CD8 + T cell population that sustains anti-tumor immunity. Immunity 54; 2825-2841 (2021)
to top
powered by webEdition CMS